Polyunsaturated fatty acid supplementation for schizophrenia

Area of Science:

• Neuroscience and Psychiatry
• Nutritional Psychiatry
• Pharmacological Interventions

Background:

• Schizophrenia symptoms may stem from altered neuronal membrane structure and metabolism.
• Essential fatty acid levels in blood plasma influence neuronal membrane integrity and function.

Purpose of the Study:

• To systematically review the effects of polyunsaturated fatty acid (PUFA) supplementation in individuals diagnosed with schizophrenia.

Main Methods:

• Updated systematic review and meta-analysis of randomized clinical trials (RCTs) investigating PUFA treatment for schizophrenia.
• Searches conducted on the Cochrane Schizophrenia Group's Register, supplemented by direct contact with authors and pharmaceutical companies.
• Data extracted and analyzed on an intention-to-treat basis, calculating Relative Risks (RR), Number Needed to Treat (NNT), and Weighted Mean Differences (WMD) with 95% Confidence Intervals (CI).

Main Results:

• Limited trials suggest omega-3 fatty acids (E-EPA or EPA) may reduce neuroleptic requirements (RR 0.73, NNT 3) and improve mental state (RR 0.54) compared to placebo.
• No significant differences observed in study withdrawal rates or movement disorder outcomes.
• Data comparing omega-6 (GLA) or different omega-3 formulations (EPA vs. DHA) are scarce, and no significant adverse effects were linked to PUFA supplementation.

Conclusions:

• Current evidence on PUFAs for schizophrenia remains inconclusive, despite updated reviews and more included studies.
• The use of omega-3 PUFAs for schizophrenia is considered experimental.
• There is a critical need for large, well-designed, and rigorously reported studies to establish efficacy and safety.